Technology

Harnessing the Potential of Muse Cell Exosomes for Therapeutic Applications

Lab beaker with blue glove

ExoGrade exosomes are derived from umbilical cord mesenchymal stem cells (MSCs), through a patent-pending technology that expands the Muse Cell population prior to exosome isolation and purification.

Perinatal Multilineage Stress-enduring (MUSE) Cells:

  • can survive in harsh environments, as found in injured or damaged tissue
  • can home to the site of injury or damage
  • are pluriopotent – they can support and differentiate into cells of the ectodermal, endodermal and mesodermal lineages
  • can self-renew
  • are non-tumorigenic
How ExoGrade Exosomes are produced

Manufacturing

Manufacturing exosome-based therapies requires precision and innovation. ExoGrade utilizes state-of-the-art facilities to produce and isolate exosomes at scalable levels. Our proprietary, patent-pending method for expansion and isolation of Muse Cell exosomes ensures that we deliver the highest quality and potency in every batch. This process is optimized for clinical-grade production, adhering to strict regulatory guidelines to ensure the safety and efficacy of our therapeutics. As we prepare for our EMA First-in-Human clinical trials in Vilnius, Lithuania, set for early 2025, we continue refining our manufacturing processes to meet global healthcare standards.

How ExoGrade Exosomes are produced

Exosome Production

Intellectual Property

Innovation is at the heart of ExoGrade's mission, and our intellectual property strategy reflects that. We are proud to have developed a patent-pending process for the expansion of Muse Cells and the isolation of their exosomes. This groundbreaking method ensures that ExoGrade remains at the forefront of exosome-based therapies, safeguarding our research and enabling us to drive forward the development of life-saving treatments. Our intellectual property portfolio is designed to protect our advancements while fostering continued innovation in the biotech space.